

ROMANIA

Confidence Building Measure Return (covering data for 2020)

**Convention on the Prohibition of the Development,
Production and Stockpiling of Bacteriological
(Biological) and Toxin Weapons and on their
Destruction, 10 April 1972**

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: **15 October 2021**

State Party to the Convention: **ROMANIA**

Date of ratification/accession to the Convention: **25 July 1979**

National point of contact: **OSCE, Non-Proliferation and Arms Control Directorate**

Ministry of Foreign Affairs

Tel. : +40 21 431 1262, Fax: +40 21 431 1804

E-mail: don@mae.ro

Active promotion of contacts

The Third Review Conference agreed that States parties continue to implement the following:

"Active promotion of contacts between scientists, other experts and facilities engaged in biological research directly related to the Convention, including exchanges and visits for joint research on a mutually agreed basis."

In order to actively promote professional contacts between scientists, joint research projects and other activities aimed at preventing or reducing the occurrence of ambiguities, doubts and suspicions and at improving international cooperation in the field of peaceful bacteriological (biological) activities, the Seventh Review Conference encouraged States parties to share forward looking information, to the extent possible,

- on planned international conferences, seminars, symposia and similar events dealing with biological research directly related to the Convention, and
- on other opportunities for exchange of scientists, joint research or other measures to promote contacts between scientists engaged in biological research directly related to the Convention,

including through the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs.

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

At the Third Review Conference it was agreed that States Parties continue to implement the following:

"Exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a high individual and community risk or specialize in permitted biological activities directly related to the Convention."

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

Data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the latest edition of the WHO¹ Laboratory Biosafety Manual and/or OIE² Terrestrial Manual or other equivalent guidelines adopted by relevant international organisations, such as those designated as biosafety level 4 (BL4, BSL4 or P4) or equivalent standards.

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

Form A, part 1 (i)

Exchange of data on research centres and laboratories³

1. Name(s) of facility⁴ _____
2. Responsible public or private
organization or company _____
3. Location and postal address _____

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

¹ World Health Organization

² World Organization for Animal Health

³ The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

⁴ For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

5. Number of maximum containment units⁵ within the research centre and/or laboratory, with an indication of their respective size (m²)

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

⁵ In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents⁶ on a State Party's territory:

Biosafety level 3 ⁷	No (under construction)
Biosafety level 2 ⁸ (if applicable)	yes

Any additional relevant information as appropriate:

The facility operating the BSL 2+ containment laboratory is the **Military Medical Research Center**, located in Bucharest, Institutul Medico–Militar street, District 1.

As a result of its reorganization (based on the Emergency Ordinance of the Government of Romania No. 125 from August 2020), the Military Medical Research Center was incorporated in the structure of The “Cantacuzino” National Medico-Military Institute for Research and Development (“Cantacuzino” NMMIRD) with all its staff, facilities and equipments. For details, see the corresponding section of “Cantacuzino” NMMIRD.

⁶ Microorganisms pathogenic to humans and/or animals

⁷ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

⁸ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents⁹ on a State Party's territory:

Biosafety level 3 ¹⁰	yes (requires validation)
Biosafety level 2 ¹¹ (if applicable)	yes

Any additional relevant information as appropriate:

The National Institute for Infectious Diseases “Matei Balș” Bucharest (INBI MB) is the most important Romanian medical institution in charge with the management of patients with infectious diseases and consequently with victims of incidents involving biological agents. INBI MB is currently being charged by the Ministry of Health with the management of patients in case of out of the ordinary outbreaks (major, unusual, pandemic, such as the early stages of the Ebola epidemic in West Africa in 2014, when INBI MB was charged with the management of the potential Ebola infected patients on Romanian territory).

INBI MB was involved in managing patients infected with SARS-CoV-2 from the very first case in Romania and is the leading institution that coordinates the national strategy on management of COVID-19 cases. INBI MB provides scientific counselling regarding infectious diseases policies in Romania for the Ministry of Health and also performs tasks related to first response in unusual outbreaks (such as the ones triggered by SARS, MERS CoV, H7N9 or H5N1 influenza viruses etc.). INBI MB functions as the seat for the National Anti-AIDS Commission (www.cnlas.ro), managing the prevention and treatment of AIDS on national level.

INBI MB is also involved in medical research, having a very modern and state of the art equipped Centre for Biomolecular Applied Research in Infectious Diseases, **including BSL2 and BSL3 facilities**. This laboratory facility is located in a 4 floor (plus a 5th technical floor) building with over 3300 sqm and has several dedicated areas for virology, bacteriology, molecular biology, genetics, immunology, clinical biochemistry as well as imagistics (radiology, CT, MRI etc. for patient use). These laboratories are employed in diagnostic and applied research activities, including test validation, test development and microbiological surveys. The primary objectives of these facilities are to provide a capability allowing Romania to:

⁹ Microorganisms pathogenic to humans and/or animals

¹⁰ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹¹ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

- Survey human health status in relation with circulating pathogenic strains (microbiological surveillance);
- Identification of strains of certain micro-organisms not usually found in this country.

The **BSL3 facilities** are located at the second floor (areas dedicated to pathogenic fungi and Mycobacterium tuberculosis) but mainly at the 4th floor (540 sqm), with separated access from the ground level, includes a HLCC (High Level of Containment Care) infected patient management area (unique in Romania, designed for managing at least 2 patients simultaneously) as well as a nearby BSL3+ laboratory (with both glove box and level A suit systems), suited for diagnostic activities involving highly dangerous pathogens, up to P4 (including some of the select agents that have the potential to pose a severe threat to public health and safety). However, this capability refers mainly to diagnostic procedures performed on human biological samples (environmental samples will need further actions toward methods and techniques validation).

INBI MB **has no operational BSL4** and is not involved in any national biological defence research and development program.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents¹² on a State Party's territory:

Biosafety level 3 ¹³	yes (not operational)
Biosafety level 2 ¹⁴ (if applicable)	yes

Any additional relevant information as appropriate:

The “Cantacuzino” National Medico-Military Institute for Research and Development (“Cantacuzino” NMMIRD), located in Bucharest, operates several BSL2 containment laboratories (totalling 739.42 sqm) within the Department of Microbiology for Public Health (Viral Respiratory Infections Laboratory, Bacterial Respiratory Infections Laboratory, Viral Enteric Infections Laboratory, Vector Borne Diseases Laboratory, Sexually Transmitted Diseases Laboratory, Bacterial Enteric Infections Laboratory, Nosocomial Infections Laboratory, Anaerobical and Zoonosis Infections Laboratory, Parasitology, Molecular Epidemiology Laboratory) and the Department of Research and Development. These laboratories are used in diagnostic and applied research activities, including test validation, test development and microbiological surveys of bacterial, viral, parasitic and mycotic diseases.

The primary objectives of these facilities are to provide a capability allowing Romania to:

- Survey human health status in relation with circulating pathogenic strains (microbiological surveillance);
- Identification of strains of certain micro-organisms not usually found in Romania (as SARS-CoV-2 in 2020).

“Cantacuzino” NMMIRD has a BSL3 facility (totalling 175 sqm) within the Department of Microbiology for Public Health, intended for diagnostic and applied research activities. Currently the BSL3 facility is not operational, as there still are several validation procedures to be performed.

“Cantacuzino” NMMIRD has no operational BSL4.

“Cantacuzino” NMMIRD is not involved in any national biological defense research and development programme.

¹² Microorganisms pathogenic to humans and/or animals

¹³ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹⁴ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents¹⁵ on a State Party's territory:

Biosafety level 3 ¹⁶	yes
Biosafety level 2 ¹⁷ (if applicable)	yes

Any additional relevant information as appropriate:

Romania's National Sanitary Veterinary and Food Safety Authority (NSVFSA) operates a BSL3 containment laboratory, component of the **Institute for Diagnosis and Animal Health/ IDAH** (located in Bucharest, Dr. N. Staicovici street, no. 63, sector 5, zip code 050557; Phone: +40/374.322.013, Fax: . +40/21.411.33.94, e-mail: office@idah.ro , web: www.idah.ro/).

The BSL3 containment laboratory is used for diagnostic in animal health and welfare; including test validation, and surveys, and participation to the international inter-comparison and proficiency tests. Primary objectives are to have a capability allowing Romania to:

- demonstrate its animal health status; and
- demonstrate strains of certain micro-organisms not found in this country.

The Institute for Diagnosis and Animal Health is a governmental institution with public financing and has no national biological defence research and development programme.

IDAH (through its National Reference laboratories for animal health and welfare) co-ordinates the diagnosis and surveillance work on animal health of the 40 County Sanitary Veterinary and Food Safety Laboratories. It is also the National Reference Laboratory for GMO in Food and Feed.

The Institute for Diagnosis and Animal Health provides technical guidance for County Sanitary Veterinary and Food Safety Laboratories and has the responsibility of performing confirmatory tests. It has also the responsibility to organize every County Sanitary Veterinary and Food Safety Laboratory, training and continuous training activities, in order to teach the specialists working in the County Sanitary veterinary and Food Safety Laboratories.

The Institute is accredited in accordance with ISO 17025 and ISO 17043 by RENAR, national accreditation body. It also received an attestation from the National Authority for

¹⁵ Microorganisms pathogenic to humans and/or animals

¹⁶ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

¹⁷ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Scientific Research, to initiate/participate/conduct research programs in area falling within their competence.

As the main activity of the Institute for Diagnosis and Animal Health is the laboratory diagnosis in the field of animal health, it has reference materials (bacterial and viruses strains, etc.) destined strictly for the laboratory diagnostic and stored, manipulated and used in biosafety and biosecurity conditions, only by the authorized personnel.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents¹⁸ on a State Party's territory:

Biosafety level 3 ¹⁹	no
Biosafety level 2 ²⁰ (if applicable)	yes

Any additional relevant information as appropriate:

The Institute for Hygiene and Veterinary Public Health (IHVPH), located in Bucharest, Campul Mosilor street no. 5, sector 2, postal code 021201, operates several BSL2 containment laboratories. Its source of financing comes only from the National Sanitary Veterinary and Food Safety Authority.

The Institute is the national reference laboratory in the field of animal origin products, food and animal feeding stuffs. Some of the main duties include activities of guidance, proficiency tests, technical co-ordination and control of the county Sanitary Veterinary Food Safety laboratories, sanitary veterinary expertise for animal origin foodstuffs, caring out of results confirmation for laboratory testing, participation in the development of guidelines, instructions and technical details in the field of food safety and participation in the assessment proceedings for the authorization of veterinary microbiology laboratory.

The types of the micro-organisms used in daily activities are mentioned in the following table:

No.	Micro-organism	Reference
1.	<i>Aspergillus brasiliensis</i>	ATCC 16404
2.	<i>Aspergillus caesiellus</i>	ATCC 42693
3.	<i>Bacillus cereus</i>	ATCC 11778
4.	<i>Bacillus subtilis</i> subsp. <i>spizizenii</i>	ATCC 6633
5.	<i>Candida albicans</i>	ATCC 10231
6.	<i>Campylobacter coli</i>	ATCC 43478
7.	<i>Campylobacter jejuni</i>	ATCC 33291
8.	<i>Campylobacter jejuni</i>	ATCC 29428
9.	<i>Campylobacter lari</i>	ATCC 35221
10.	<i>Citrobacter freundii</i>	ATCC 43864

¹⁸ Microorganisms pathogenic to humans and/or animals

¹⁹ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

²⁰ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

11.	<i>Clostridium perfringens</i>	ATCC 13124
12.	<i>Clostridium botulinum</i> TIP F	NCTC 10281
13.	<i>Clostridium botulinum</i> TIP B	NCTC 7273
14.	<i>Clostridium botulinum</i> TIP E	NCTC 11219
15.	<i>Clostridium botulinum</i> TIP A	NCTC 11199
16.	<i>Clostridium butiricum</i>	ATCC 19398
17.	<i>Cronobacter sakazakii</i>	ATCC 29544
18.	<i>Cronobacter muytjensii</i>	ATCC 51329
19.	<i>Enterobacter cloacae</i> subsp. <i>cloacae</i>	ATCC 13047
20.	<i>Enterococcus faecalis</i>	ATCC 19433
21.	<i>Enterococcus faecalis</i>	ATCC 29212
22.	<i>Enterococcus faecium</i>	ATCC 6057
23.	<i>Escherichia coli</i>	ATCC 8739
24.	<i>Escherichia coli</i>	NCTC 12900 (serotip O157:H7)
25.	<i>Escherichia coli</i>	NCTC 13216
26.	<i>Escherichia coli</i>	ATCC 25922
27.	<i>Listeria innocua</i> serotip 6a	ATCC 33090
28.	<i>Listeria ivanovii</i> subsp. <i>ivanovii</i>	ATCC 19119
29.	<i>Listeria monocytogenes</i> serotip 4b	ATCC 13932
30.	<i>Listeria monocytogenes</i> serotip 1a	ATCC 35152
31.	<i>Proteus mirabilis</i>	ATCC 29906
32.	<i>Pseudomonas aeruginosa</i>	ATCC 10145
33.	<i>Pseudomonas aeruginosa</i>	ATCC 27853
34.	<i>Rhodococcus equi</i>	ATCC 6939
35.	<i>Saccharomyces cerevisiae</i>	ATCC 9763
36.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Choleraesuis	ATCC 10708
37.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Choleraesuis	ATCC 7001
38.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Enteritidis	ATCC 13076
39.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Abaetetuba	ATCC 35640
40.	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium	ATCC 14028
41.	<i>Staphylococcus aureus</i> subsp. <i>aureus</i>	ATCC 6538
42.	<i>Staphylococcus aureus</i> subsp. <i>aureus</i>	ATCC 25923
43.	<i>Staphylococcus epidermidis</i>	ATCC 12228
44.	<i>Vibrio cholerae</i>	NCTC 11348
45.	<i>Vibrio furnissii</i>	NCTC 11218
46.	<i>Vibrio parahaemolyticus</i>	NCTC 10884
47.	<i>Vibrio parahaemolyticus</i>	NCTC 10885
48.	<i>Vibrio parahaemolyticus</i>	NCTC 10903
49.	<i>Vibrio parahaemolyticus</i>	NCTC 10885
50.	<i>Vibrio parahaemolyticus</i>	ATCC 17802
51.	<i>Vibrio vulnificus</i>	NCTC 13647
52.	<i>Wallemia mellicola</i>	ATCC 42694
53.	<i>Yersinia enterocolitica</i> subsp. <i>enterocolitica</i>	ATCC 23715
54.	<i>Yersinia enterocolitica</i>	NCTC 11174
55.	<i>Yersinia enterocolitica</i>	NCTC 10598
56.	<i>Yersinia intermedia</i>	NCTC 11469

57.	<i>Yersinia pseudotuberculosis</i>	NCTC 10275
58.	<i>Yersinia enterocolitica</i> paelearctica O	NCTC 13769
59.	<i>E. coli</i> O103	ref. EURL <i>E. coli</i> B07
60.	<i>E. coli</i> O111	ref. EURL <i>E. coli</i> A07
61.	<i>E. coli</i> O157	ref. EURL <i>E. coli</i> C07
62.	<i>E. coli</i> O145	ref. EURL <i>E. coli</i> E07
63.	<i>E. coli</i> O26	ref. EURL <i>E. coli</i> D07
64.	<i>E. coli</i> O104:K-H12	ref. EURL <i>E. coli</i> H519
65.	<i>E. coli</i> O113:H21	ref. EURL <i>E. coli</i> 6182-50
66.	<i>E. coli</i> O55:H-	ref. EURL <i>E. coli</i> Su 3912-41
67.	<i>E. coli</i> O121:K-H10	ref. EURL <i>E. coli</i> 39w
68.	<i>E. coli</i> O128ab:H2	ref. EURL <i>E. coli</i> Cigleris
69.	<i>E. coli</i> O146:K-H21	ref. EURL <i>E. coli</i> CDC2950-54
70.	<i>E. coli</i> O91:K-H-	ref. EURL <i>E. coli</i> H307B
71.	<i>E. coli</i> O104:H4	ref. EURL <i>E. coli</i> D4116
72.	<i>Salmonella</i> Braenderup	ref. EURL <i>E. coli</i> H9812
73.	<i>E. coli</i>	ref. EURL SSI-NN14
74.	<i>E. coli</i>	ref. EURL EA22
75.	<i>E. coli</i>	ref. EURL SSI-OO15
76.	<i>E. coli</i>	ref. EURL <i>E. coli</i> D2653
77.	<i>E. coli</i>	ref. EURL <i>E. coli</i> D3602
78.	<i>E. coli</i>	ref. EURL <i>E. coli</i> D3522
79.	<i>E. coli</i>	ref. EURL <i>E. coli</i> D3428
80.	<i>E. coli</i>	ref. EURL <i>E. coli</i> D3648
81.	<i>E. coli</i>	ref. EURL <i>E. coli</i> D3546
82.	<i>E. coli</i>	ref. EURL <i>E. coli</i> D3509
83.	<i>E. coli</i>	ref. EURL <i>E. coli</i> D3431
84.	<i>E. coli</i>	ref. EURL <i>E. coli</i> D4134
85.	<i>Staphylococcus aureus</i>	ref. EURL CPS FRI 137
86.	<i>Staphylococcus aureus</i>	ref. EURL CPS FRI 361
87.	<i>Staphylococcus aureus</i>	ref. EURL CPS A900322
88.	<i>Staphylococcus aureus</i>	ref. EURL CPS FRI S6
89.	<i>Staphylococcus aureus</i>	ref. EURL CPS FRI 326
90.	<i>Listeria monocytogenes</i>	ref. Anses 00EB248LM ref. colectie Inst. Pasteur Clip74902
91.	<i>Listeria monocytogenes</i>	ref. Anses 00EB249LM ref. colectie Inst. Pasteur Clip74903
92.	<i>Listeria monocytogenes</i>	ref. Anses 00EB250LM .ref. colectie Inst. Pasteur Clip74904
93.	<i>Listeria monocytogenes</i>	ref. Anses 00EB254LM ref. colectie Inst. Pasteur Clip74908
94.	<i>Listeria monocytogenes</i>	ref. Anses 00EB256LM ref. colectie Inst. Pasteur Clip74910
95.	<i>E. coli</i> ESBL AmpC martor +	2005-10-96-1K99+ EURL AR
96.	<i>E. coli</i> ESBL AmpC martor -	OXA-30 EURL AR
97.	<i>E. coli</i> control CARBAPENEMAZE	TZ3638 EURL AR
98.	<i>E. coli</i> control CARBAPENEMAZE	TZ 116 EURL AR
99.	<i>E. coli</i>	ATCC 16874
100.	<i>Enterococcus faecalis</i>	ATCC 29212 ref. EURL-AR
101.	<i>E. coli</i>	ATCC 25922 ref. EURL-AR
102.	<i>Staphylococcus aureus</i>	ATCC 29213 ref. EURL-AR

103.	Salmonella infantis	ref. EURL Salmonella
104.	Campylobacter jejuni	ATCC 33560 ref. EURL-AR
105.	Bacillus cereus	NCTC 11143
106.	Norovirus G I	lenticule disc-Certified Reference Material from Public Health England and reference materials from European Union Reference Laboratory for foodborne viruses
107.	Norovirus G II	lenticule disc-Certified Reference Material from Public Health England and reference materials from European Union Reference Laboratory for foodborne viruses
108.	Hepatitis A virus	lenticule disc-Certified Reference Material from Public Health England and reference materials from European Union Reference Laboratory for foodborne viruses
109.	Clostridium botulinum type B	Strain isolated by IHVPH in food
110.	Clostridium botulinum type E	Strain isolated by IHVPH in food
111.	Clostridium botulinum TIP A	NCTC 11199
112.	Clostridium botulinum type B	NCTC 7273 Public Health England
113.	Clostridium botulinum type E	NCTC 7272 Public Health England
114.	Clostridium botulinum type F	NCTC 10281 Public Health England
115.	Vibrio vulnificus	NC 13647 Public Health England
116.	Vibrio cholerae	NC 11348 Public Health England
117.	Vibrio parahaemolyticus	NC 10885 Public Health England
118.	Vibrio parahaemolyticus	NC 10884 Public Health England
119.	Vibrio parahaemolyticus	NC 10903 Public Health England

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents²¹ on a State Party's territory:

Biosafety level 3 ²²	no
Biosafety level 2 ²³ (if applicable)	yes

Any additional relevant information as appropriate:

The Institute for Control of Veterinary Biological Products and Medicines (ICVBPM), located in Bucharest, 39 Dudului Street, sector 6, Romania, is a unit with juridical status, functioning as a national reference institute, under the technical subordination of the National Sanitary Veterinary and Food Safety Authority. ICVBPM has competence in the field of veterinary medicinal products, biocides, feed additives, diagnosis sets, other veterinary products (vitamins, mineral supplements and cosmetics).

The main task with relevance on these issues is quality control of veterinary of live and inactivated vaccines for bacterial, viral, parasites:

- live vaccines against distemper, infectious hepatitis, infectious laryngotracheitis, parvovirus and parainfluenza in dogs,
- inactivated vaccine for rabies,
- live and inactivated vaccines for panleucopenia, calicivirus and herpesvirus infection of cats,
- live and inactivated vaccines for IBR, BVD and SRB of bovine,
- rabies live vaccine for oral immunization in foxes,
- live vaccines against Aujeszky virus for pigs,
- live vaccine against myxomatosis and inactivated vaccines for Infectious Rabbit Hemorrhagic Disease,
- live vaccine against infectious bronchitis in poultry, infectious bursitis in poultry (Gumboro disease), Newcastle disease in poultry, inactivated vaccine against the egg drop syndrome, Inactivated vaccine against Newcastle disease and infectious bursitis in poultry,
- vaccine against porcine parvovirus, inactivated,
- vaccine against leptospirosis in dogs and furry animals,
- inactivated vaccine against equine influenza and tetanus,
- inactivated vaccines against parvovirus and swine erysipelas,
- live vaccine against anthrax with B. Anthracis, attenuated strain 1190 R,
- live vaccines for Salmonella in poultry,
- vaccine inactivated against avian Cholerae.

²¹ Microorganisms pathogenic to humans and/or animals

²² In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

²³ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Quality control of veterinary pharmaceutical products (antimicrobial, anti-inflammatory, antiparasitics, etc.). To perform the quality control of pharmaceutical products is used the microorganisms test as bellow:

- Staphylococcus aureus ATCC 6538,
- Bacillus subtilis ATCC 6633, NCTC 2589,
- Pseudomonasaeruginosa ATCC 9027,
- Clostridium sporogenes ATCC 11437,
- Candida albicans ATCC 10231,
- Aspergillus Brasiliensis ATCC16404,
- Escherichia coli ATCC 8739, ATCC 10536, ATCC 1133,
- Salmonella enterica subsp. Enterica serovariant typhimurium ATCC 14028,
- Saccharomyces cerevisiae ATCC 2601,
- Micrococcus luteus ATCC 10240, ATCC 9341,
- Bordetella bronchiseptica ATCC 4617,
- Bacillus pumilus NCTC 8241, CIP 76.18,
- Staphylococcus epidermitis NCIMB 8853, CIP 68.21, ATCC 12228,
- Candida tropicalis CIP 1433-83, NCYC 1393,
- Bacillus spizizenii ATCC 4617,
- Streptococcus faecalis 8043.

Diagnostic test kits: for viral, bacterial and parasites disease by following tests: ELISA, immunodifusion test, complement bond reaction, slow and quick agglutination, immunofluorescent test, immunoperoxidase test.

Quality control of immunological veterinary medicinal products: Tuberculines avian and bovines (PPD) by using inactivated strains of Mycobacterium bovis and avium.

The laboratory's activities are organized and performed according to ISO 17025:2005 requirements and ISO 9001:2008 requirements.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents²⁴ on a State Party's territory:

Biosafety level 3 ²⁵	no
Biosafety level 2 ²⁶ (if applicable)	yes

Any additional relevant information as appropriate:

The facility operating BSL2 containment laboratories is the research department of the **National Society "Pasteur Institute" SA - CENTER FOR RESEARCH AND DEVELOPMENT, DIAGNOSTIC AND QUALITY CONTROL** (Giulesti street no. 333, sector 6, Postal Code 060269, Bucharest). The source of financing of the reported activity is Pasteur Filipesti Branch SA.

The research activity regards animal viruses and bacteria (*Escherichia coli*, *Actinobacillus pleuropneumoniae*, *Erysipelothrix rhusiopathiae*, Aujeszky virus, avian laryngotracheitis virus, avian coronavirus, avipox viruses, avian bursitis virus, avian paramyxoviruses, *Mycoplasma agalactiae*, *Clostridium perfringens*, *Clostridium septicum*, *Clostridium novyi*, *Clostridium chauvoei*, *Leptospira* spp.). Veterinary immunoprophylactic and pharmaceutical products, but also *in vivo* and *in vitro* diagnostic products are also provided.

The laboratories activities are organized in accordance to ISO 9001:2008 and for some of their methods to ISO 17025:2005 requirements.

²⁴ Microorganisms pathogenic to humans and/or animals

²⁵ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

²⁶ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

- (1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;
- (2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;
- (3) The organizational structure of the programme and its reporting relationships; and
- (4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;
 - (a) location;
 - (b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;
 - (c) the total number of staff employed, including those contracted full time for more than six months;
 - (d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;
 - (e) a list of the scientific disciplines of the scientific/engineering staff;
 - (f) the source and funding levels in the following three areas: research, development, and test and evaluation; and
 - (g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on

pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes/No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.
2. State the total funding for each programme and its source.
3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes/No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?
5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.
6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).
7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

2. Where is it located (include both address and geographical location)?

3. Floor area of laboratory areas by containment level:

BL2 _____ (sqM)

BL3 _____ (sqM)

BL4 _____ (sqM)

Total laboratory floor area _____ (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel _____

(ii) Division of personnel:

Military _____

Civilian _____

(iii) Division of personnel by category:

Scientists _____

Engineers _____

Technicians _____

Administrative and support staff _____

(iv) List the scientific disciplines represented in the scientific/engineering staff.

(v) Are contractor staff working in the facility? If so, provide an approximate number.

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

(vii) What are the funding levels for the following programme areas:

Research _____

Development _____

Test and evaluation _____

(viii) Briefly describe the publication policy of the facility:

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms²⁷ and/or toxins studied, as well as outdoor studies of biological aerosols.

²⁷ Including viruses and prions.

Confidence-Building Measure "B"

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

At the Third Review Conference it was agreed that States Parties continue to implement the following:

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins, and on all such events that seem to deviate from the normal pattern as regards type, development, place, or time of occurrence. The information provided on events that deviate from the norm will include, as soon as it is available, data on the type of disease, approximate area affected, and number of cases.

The Seventh Review Conference agreed the following:

No universal standards exist for what might constitute a deviation from the normal pattern.

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

1. Exchange of data on outbreaks that seem to deviate from the normal pattern is considered particularly important in the following cases:

- When the cause of the outbreak cannot be readily determined or the causative agent²⁸ is difficult to diagnose,
- When the disease may be caused by organisms which meet the criteria for risk groups III or IV, according to the classification in the latest edition of the WHO Laboratory Biosafety Manual,
- When the causative agent is exotic to a given geographical region,
- When the disease follows an unusual pattern of development,
- When the disease occurs in the vicinity of research centres and laboratories subject to exchange of data under item A,
- When suspicions arise of the possible occurrence of a new disease.

2. In order to enhance confidence, an initial report of an outbreak of an infectious disease or a similar occurrence that seems to deviate from the normal pattern should be given promptly after cognizance of the outbreak and should be followed up by annual reports. To enable States Parties to follow a standardized procedure, the Conference has agreed that Form B should be used, to the extent information is known and/or applicable, for the exchange of annual information.

3. The declaration of electronic links to national websites or to websites of international, regional or other organizations which provide information on disease outbreaks (notably outbreaks of infectious diseases and similar occurrences caused by

²⁸ It is understood that this may include organisms made pathogenic by molecular biology techniques, such as genetic engineering.

toxins that seem to deviate from the normal pattern) may also satisfy the declaration requirement under Form B.

4. In order to improve international cooperation in the field of peaceful bacteriological (biological) activities and in order to prevent or reduce the occurrence of ambiguities, doubts and suspicions, States Parties are encouraged to invite experts from other States Parties to assist in the handling of an outbreak, and to respond favourably to such invitations, respecting applicable national legislation and relevant international instruments.

Form B

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern²⁹

1. Time of cognizance of the outbreak _____
2. Location and approximate area affected _____
3. Type of disease/intoxication _____
4. Suspected source of disease/intoxication _____
5. Possible causative agent(s) _____
6. Main characteristics of systems _____
7. Detailed symptoms, when applicable _____
 - respiratory _____
 - circulatory _____
 - neurological/behavioural _____
 - intestinal _____
 - dermatological _____
 - nephrological _____
 - other _____
8. Deviation(s) from the normal pattern as regards _____
 - type _____
 - development _____
 - place of occurrence _____
 - time of occurrence _____
 - symptoms _____
 - virulence pattern _____
 - drug resistance pattern _____
 - agent(s) difficult to diagnose _____
 - presence of unusual vectors _____
 - other _____
9. Approximate number of primary cases _____
10. Approximate number of total cases _____
11. Number of deaths _____
12. Development of the outbreak _____
13. Measures taken _____

²⁹ See paragraph 2 of the chapeau to Confidence-Building Measure B.

Confidence-Building Measure "C"

Encouragement of publication of results and promotion of use of knowledge

At the Third Review Conference it was agreed that States parties continue to implement the following:

Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research.

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, *inter alia*, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Romania encourages publication of results of biological research directly related to the Convention provided it is in compliance with good biosecurity practices.

- **Published papers generated through research and development activities performed within "Cantacuzino" NMMIRD in 2020**

No.	Title of the published scientific paper	Name of the Scientific Journal	Authors	Additional information
1	The extraction procedure and cyclic voltammetry assay using screen printed electrodes for detection of monosodium glutamate from different processed food sources	Revista de Chimie	Dora Domnica Baci, Aurora Sălăgeanu, Teodor Vișan	https://doi.org/10.37358/RC.20.2.7947
2	Generation of a 3D melanoma model and visualization of doxorubicin uptake by fluorescence imaging	Analytical Biochemistry: Methods in the Biological Sciences	Baci, D.D, Dumitrașcu, A.M, Vasile, V., Palade, B, Sălăgeanu, A	Under peer review

3	<i>Saccharomyces cerevisiae</i> cells lacking transcription factors Skn7 or Yap1 exhibit different susceptibility to cyanidin	Heliyon	Ruta, L.L., Oprea, E., Popa, C.V., Farcasanu, I.C.	https://doi.org/10.1016/j.heliyon.2020.e05352
4	Edible and functionalized films/coatings-performances and perspectives	Coatings	Avramescu, S.M., Butean, C., Popa, C.V., Ortan A., Moraru, I., Temocico, G.	https://doi.org/10.3390/coatings10070687
5	Resistance and features of <i>Bacteroides</i> spp. isolated from abdominal infections in romanian patients	Pathogens, vol.9, Nr.11/2020.	Pricop R.G., Gheorghe I., Pircalabioru G., Cristea C.V., Popa M., Marutescu L., Chifiriuc M.C., Mihăescu G	-
6	Antibiotherapy: latest current affairs – state of the art 2019	Vol. CXXIII • No. 2/2020 • May • Romanian Journal of Military Medicine	Viorel Ordeanu, Lucia E. Ionescu, Victoria G. Dumitrescu, Roxana G. Pricop, Răzvan Neagu, Diana M. Popescu	-
7	The strategic need for the implementation of a technological platform for the microproduction of antidotes for the CBRN medical protection	Vol. CXXIII • No. 3/2020 • August • Romanian Journal of Military Medicine	Viorel Ordeanu, Adrian A. Andrieș, Lucia E. Ionescu, Marius Necșulescu, Diana M. Popescu	-
8	Medical devices in current medicine	Vol. CXXIII • No. 4/2020 • November • Romanian Journal of Military Medicine	Viorel Ordeanu, Lucia E. Ionescu, Victoria G. Dumitrescu, Roxana G. Pricop, Răzvan Neagu, Diana M. Popescu	-
9	Effect of Different Antioxidants on X-ray Induced DNA Double-strand Breaks Using γ -H2AX in Human Blood Lymphocytes	Health Physics	Nicoleta Simona Bicheru, Cerasela Haidoiu, Octavian Călborean, Adrian Popa, Ioana Porosnicu, Radu Hertzog	10.1097/HP.0000000000001267
10	Hypoxic preconditioning - a non-pharmacological approach in COVID-19 prevention	International Journal of Infectious Diseases	Radu Gabriel Hertzog, Nicoleta Simona Bicheru, Diana Mihaela Popescu, Octavian Călborean, Ana-Maria Catrina	10.1016/j.ijid.2020.11.181
11	Radiotherapy in the fight against pneumonia associated with SARS-CoV-2	International Journal of Radiation Biology	Radu Gabriel Hertzog, Nicoleta Simona Bicheru	10.1080/09553002.2020.1822560
12	The Synthesis and Toxicological Characterization of Neurotoxic Chemical Agents Simulants ..	Revista de Chimie vol 70 no.11.nov.2019	Mihai Silviu Tudosie, Cristina Anca Secară, Cătălin-Gabriel Smarandache, Simona Bicheru, Constantin Drăghici	https://doi.org/10.37358/RC.70.19.11.7664
13	The synthesis and in vitro testing of symmetric bispiridinium compounds active in the exposure to neurotoxic chemical agents	Vol. CXXIII • No. 2/2020 • May • Romanian Journal of Military Medicine	Cristina Anca Secară, Bogdan Patrinihi, Simona Bicheru, Mihai Tudosie	http://www.revistamedicina militar.ro/

14	Differential diagnosis in case of overdose of antiepileptic treatment. Clinical case,	Vol. CXXIII • No. 1/2020 • May Romanian Journal of Military Medicine	Mihail S. Tudosie, Genica Caragea, Ana D. Radu, Ileana D. Dănescu,	http://www.revistamedicina militară.ro/
15	Study regarding the determination of valproic acid serum levels by EMIT	Revista Farmacia, nr. 5, 2020	Mihail S. Tudosie, Genica Caragea, Ileana Dănescu, Radu Macovei	www.FarmaciaJournal.com http://doi.org/10.1031925/farmacia.2020.5.17
16	Comprehensive characterization of silica-modified silicon rubbers	Journal of the Mechanical Behavior of Biomedical Materials	Chiulan, Ioana; Panaitescu, Denis Mihaela; Radu, Elena-Ruxandra; Frone, Adriana Nicoleta; Gabor, Raluca Augusta; Nicolae, Cristian Andi; Jinescu, George; Tofan, Vlad; Chinga-Carrasco, Gary	10.1016/J.JM.BBM.2019.10.3427
17	Relationship between chemokines and T lymphocytes in the context of respiratory allergies (Review)	Experimental and Therapeutic Medicine	Nicolae Ovidiu Berghi, Mihai Dumitru, Daniela Vrînceanu, Radu Constantin Ciuluvica, Anca Simioniuc-Petrescu Ramona Caragheorgheopol, Catalin Tucureanu Roxana Sfrent Cornateanu, Călin Giurcaneanu	10.3892/etm.2020.8961
18	Bacterial cellulose sponges obtained with green cross-linkers for tissue engineering	Materials Science and Engineering: C Volume 110, May 2020, 110740	Frone, A.N., Panaitescu, D.M, Nicolae, C.A., Gabor, A.R., Trusca, R., Casarica, A., Stănescu, P.O., Băciu, D.D., Sălăgeanu, A	10.1016/j.msec.2020.110740
19	In vitro Evaluation of the Antiproliferative Effect, Cytotoxicity and Proinflammatory Activity of the Food Additive Monosodium Glutamate on RAW 264.7 Cell Line	Revista de Chimie, March 2020, Volume 71, Issue 2, 443-448	Dora Domnica Băciu, Aurora Sălăgeanu, Teodor Vișan	10.37358/RC.20.2.7947
20	Factorial design optimization of polystyrene microspheres obtained by aqueous dispersion polymerization in the presence of poly(2-ethyl-2-oxazoline) reactive stabilizer	Polymer International	Tanța - Verona Iordache, Nicoleta D Banu, Elena D Giol, Dumitru M Vuluga, Florica A Jerca, Valentin V Jerca	https://doi.org/10.1002/pi.5974
21	Fever temperatures abolish bacterial hemolysis: a microcalorimetry investigation	Archives of Biochemistry and Biophysics	Mihaela Palela, Elena-Diana Giol, Andreia Anzuța, Oxana G Ologu, Razvan C Stan	in press
22	Fever temperatures abolish bacterial hemolysis: a microcalorimetry investigation	bioRxiv- The preprint server for biology	Mihaela Palela, Elena-Diana Giol, Andreia Amzuța, Oxana G Ologu, Razvan C Stan	https://doi.org/10.1101/2020.11.23.393553

23	The Beneficial Mechanical and Biological Outcomes of Thin Copper-Gallium Doped Silica-Rich Bio-Active Glass Implant-Type Coatings	Coatings	George E. Stan, Teddy Tite, Adrian-Claudiu Popa, Iuliana Maria Chirica, Cătălin C. Negrilă, Cristina Beșleagă , Irina Zgura, Any Cristina Sergentu, Gianina Popescu-Pelin, Daniel Cristea, Lucia E. Ionescu , Marius Necșulescu, Hugo R. Fernandes and José M. F. Ferreira	doi:10.3390/coatings1011119
24	Composite nanogels based on zeolite - poly(ethylene glycol) diacrylate for controlled drug delivery	Nanomaterials	Cătălina Paula Spătăreanu, Anita-Laura (Radu) Chiriac, Bogdan Cursaru, Tața-Verona Iordache, Ana-Mihaela Gavrilă, Crina-Thea Cojocaru, Razvan-Edward Botez, Bogdan Trica, Andrei Sârbu, Mircea Teodorescu, Vlad Tofan, Francois-Xavier Perrin, Anamaria Zaharia	10.3390/nano10020195
25	Antibiotherapy: latest current affairs – state of the art 2019	Vol. CXXIII • No. 2/2020 • May • Romanian Journal of Military Medicine	Viorel Ordeanu, Lucia E. Ionescu, Victoria G. Dumitrescu, Roxana G. Pricop, Răzvan Neagu, Diana M. Popescu	-
26	The strategic need for the implementation of a technological platform for the microproduction of antidotes for the CBRN medical protection	Vol. CXXIII • No. 3/2020 • August • Romanian Journal of Military Medicine	Viorel Ordeanu , Adrian A. Andrieș, Lucia E. Ionescu, Marius Necșulescu , Diana M. Popescu	-
27	Diabetic nephropathy associates with deregulation of enzymes involved in kidney sulphur metabolism	Journal of cellular and molecular medicine,24 (20), 12131-12140	Elena Uyy, Viorel Iulian Suica, Raluca Maria Boteanu, Florentina Safciuc, Aurel Cerveanu - Hogas, Luminita Ivan, Crina Stavaru, Maya Simionescu, Felicia Antohe	Online ISSN:1582-4934
28	Implications of the one health concept in agriculture	Scientific Works. Series C. Veterinary Medicine. Vol. LXVI (1), 2020 ISSN 2065-1295; ISSN 2343-9394 (CD-ROM); ISSN 2067-3663 (Online); ISSN-L 2065-1295	Viorel Ordeanu, Marius Necșulescu, Diana M. Popescu, Lucia E. Ionescu	-

29	"To be or not to be" Cat de real este diagnosticul infectiei COVID-19	Romanian Journal of Infectious Diseases 2020 23(2)	Sorin Bivolaru, Oana Cristina Voinea, Manuela Arbune	http://10.37897/RJID.2.16
30	Analysis of blood parameters in a study of metabolic syndromes induction by purified diets in mice	Romanian Archives of Microbiology and Immunology	Simona Popoiu, Ana-Maria Teodoru, Nicolae Levandovschi, Cristin Coman	-
31	The relationship between chemokine ligand 3 and allergic rhinitis	Cureus April 22, 2020, 12(4): e7783. doi:10.7759/cureus.7783	Berghi O, Dumitru M, Caragheorgheopol Ramona, Tucureanu Catalin, Simioniuc-Petrescu A, Sfrent-Cornateanu R, Giurcaneanu C.	10.7759/cureus.7783
32	Diferențierea genotipică a unor tulpini de S. intermedius și S. pseudintermedius izolate de la câini și pisici	Revista Romana de Medicina Veterinara, 30, 3: 81-84	Iulia Bucur, N. Cătana, M. Necșulescu, K. Imre, V. Herman, Ileana Nichita, E. Tîrziu	-
33	The antibacterial and antibiofilm effects of humulus lupulus l. essential oil	Social Science Research Network SSRN	Gabriela Costache, Mona Luciana Gălățanu, Mariana Popescu, Lucia Elena Ionescu, Roxana Pricop, Răzvan Neagu, Viorel Ordeanu.	-
34	The impact of the covid-19 pandemic on national and international security	Proceedings	Viorel Ordeanu, Lucia E. Ionescu	-
35	Concepția de realizare a unei platforme tehnologice pentru antidoturi specifice de protecție medicală cbrn	Revista de Științe Militare	Viorel Ordeanu, Constantin Mircioiu	-
36	What do we owe to Henrietta Lacks? Considerations on the ethics of biobanking”	Romanian Archives of Microbiology and Immunology, 79(1): 54-67	Alexandra-Maria Nășcuțiu, Andreea-Roxana Lupu,	-
37	Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm096B.1A5A genetic subclades in the WHO European Region, 2018–2019	Vaccine, Volume 38, Issue 35, 31 July 2020 (pg 5707-5717)	Angeliki Melidou, Olav Hungnes, Dmitriy Pereyaslov, Cornelia Adlhoch, Hannah Segaloff, Emmanuel Robesyn, Pasi Penttinen, Sonja J. Olsen, European Region influenza surveillance network (Romania: Lazăr M, Cherciu C.)	
38	Surveillance of medically-attended influenza in elderly patients from Romania – data from three consecutive influenza seasons (2015/16, 2016/17 and 2017/18)	Influenza and Other Respiratory Viruses, 15 May 2020	Pițigoi D, Streinu-Cercel A, Ivanciuc A E, Lazăr M. Cherciu C M, Mihai M.E., Nițescu M, Aramă V, Crăciun M D, Streinu-Cercel A, Săndulescu O.	

• **Other scientific papers published in 2020 as a collaborative work of “Cantacuzino” NMMIRD with local and foreign institutions**

1. Rose A , Kissling E, Gherasim A, Casado I, Bella A, Launay O , Lazăr M, Marbus S, Kuliese M, Syrjänen R, Machado A, Kurečić Filipović S, Larrauri A, Castilla J, Alfonsi V, Galtier F, Ivanciuc A, Meijer A, Mickiene A, Ikonen N, Gómez V, Lovrić Makarić Z, Moren A, Valenciano M, I-MOVE Hospital study team Vaccine effectiveness against influenza A(H3N2) and B among laboratory confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine, *Influenza and Other Respiratory Viruses*, 05 February 2020 <https://doi.org/10.1111/irv.12714>
2. Georgiana V. Tiron, Ioana G. Stancu, Sorin Dinu, Florian L. Prioteasa, Elena Fălcută, Cornelia S. Ceianu, Ani I. Cotar. Characterization and host-feeding patterns of *Culex pipiens* s.l. taxa in an endemic West Nile virus area in southeastern Romania. *Vector Borne and Zoonotic Diseases*.
3. Corneliu P Popescu, Ani I Cotar , Sorin Dinu, Mihaela Zaharia, Grațielă Tardei, Emanoil Ceaușu, Daniela Bădescu, Simona Ruță, Cornelia S. Ceianu, Symin Aysel Florescu. Emergence of Toscana virus in Romania. *Emerging Infectious Diseases*. (IF 6.259)
4. Georgeta Cristina Oprea, Sorin Dinu, Maria Damian, Veronica Lazar. Methods use for direct detection of *Bordetella pertussis* infections in Romania. *Rom Biotechnol Lett* 25 (4): 1696-1700, 2020
5. Băicuș A, Joffret ML, Bessaud M, Delpeyroux F, Oprea G. Reinforced poliovirus and enterovirus surveillance in Romania, 2015-2016. *Arch Virol*. 2020 Nov;165(11):2627-2632. doi: 10.1007/s00705-020-04772-7
6. Oprea M, Militaru MC, Ciontea AS, Cristea D, Cristea V, Usein CR. Characterization of antibiotic resistance integrons harbored by Romanian *Escherichia coli* uropathogenic strains. *Rev Romana Med Lab*. 2020;28(3):331-40. DOI:10.2478/rmlm-2020-0023.
7. Oprea M, Njamkepo, E, Cristea D. et al. The seventh pandemic of cholera in Europe revisited by microbial genomics. *Nat Commun* 11, 5347 (2020) <https://doi.org/10.1038/s41467-020-19185-y>
8. Elena Fălcută, Liviu Florian Prioteasa, Cintia Horváth, Ioana Raluca Păstrav, Francis Schaffner, Andrei Daniel Mihalca. The invasive Asian tiger mosquito *Aedes albopictus* in Romania: towards a country-wide colonization? *Parasitology Research* (2020) 119:841–845
9. Romeo Bellinia, Antonios Michaelakis, Dušan Petrić, Francis Schaffner, Bulent Alten, Paola Angelini, Carles Arandag, Norbert Becker, Marco Carrieri, Marco Di Lucaj, Elena Fălcută et al., Practical management plan for invasive mosquito species in Europe: I. Asian tiger mosquito (*Aedes albopictus*), April 2020, *Travel Medicine and Infectious Disease* 35, DOI: 10.1016/j.tmaid.2020.101691.
10. Dragomirescu CC, Lixandru BE, Coldea IL, Corneli ON, Pană M, Palade AM, Cristea CV, Suci I, Suci G, Manolescu LSC, Popa GL, Popa MI. Antimicrobial susceptibility testing for *Corynebacterium* species isolated from clinical samples in Romania. *Antibiotics*. 2020;9(1):31 doi:10.3390/antibiotics9010031 CA .
11. Leopold Tie, Mina Răileanu, Mihaela Bacalum, Irina Codita, Ștefania Mădălina Negrea, Costin Ștefan Caracoti, Elena-Carmina Drăgulescu, Andreea Campu, Simion Astilean, Monica Focsan. Versatile Polypeptide-Functionalized Plasmonic Paper as

Synergistic Biocompatible and Antimicrobial Nanoplatform. *Molecules*. 2020 Jul; 25(14): 3182, doi: 10.3390/molecules25143182.

12. Felix Lötsch, Barbara Albiger, Dominique L. Monnet, Marc J. Struelens, Harald Seifert, Anke Kohlenberg, European Antimicrobial Resistance Genes Surveillance Network (EURGen-Net) carbapenem-resistant *Acinetobacter baumannii* capacity survey group (....Romania – Irina Codiță....). Epidemiological situation, laboratory capacity and preparedness for carbapenem-resistant *Acinetobacter baumannii* in Europe, 2019. . *Euro Surveill*. 2020;25(45):pii=2001735.

13. Davies K, Lawrence J, Berry C, Davis G, Yu H, Cai B, Gonzalez E, Prantner I, Kurcz A, Macovei I, Pituch H, Nováková E, Nyc O, Gärtner B, Berger FK, Oleastro M, Cornely OA, Vehreschild MJGT, Pedneault L and Wilcox M, 2020. Risk factors for primary *Clostridium difficile* infection; results from the observational study of risk factors for *Clostridium difficile* infection in hospitalized patients with infective diarrhea (ORCHID). *Frontiers in Public Health*, 8: 293. <https://doi.org/10.3389/fpubh.2020.00293>.

14. Băncescu G, Dabu B, Băncescu A. Detectarea producerii de β -lactamază la izolatele de *Prevotella* cu pigment negru din orofaringele adulților tineri [abstract]. *Rev Romana Med Lab* 2020;28(4) suppl 1:S22.

15. Georgeta Cristina Oprea- „The virulence factors involved in *Bordetella pertussis* pathogenesis and their genetic regulation”- articol acceptat spre publicare in revista *Romanian Archives for Microbiology and Immunology* nr. 2/2020.

• **Published papers generated through research and development activities performed within The National Institute for Infectious Diseases “Matei Balș” (INBI MB) in 2020**

1. Surleac M, Casangiu C, Banica L, Milu P, Florea D, Sandulescu O, Streinu-Cercel A, Vlaicu O, Tudor A, Hohan R, Paraschiv S, Otelea D. Evidence of novel SARS-CoV-2 variants circulation in Romania. *AIDS Res Hum Retroviruses*. 2021 Feb 5. doi: 10.1089/AID.2021.0009. Online ahead of print. ISSN: 0889-2229, eISSN: 1931-8405. Factor de impact (2019): 1.823.
2. Popa LI, Gheorghe I, Barbu IC, Surleac M, Paraschiv S, Măruțescu L, Popa M, Pîrcălăbioru GG, Talapan D, Niță M, Streinu-Cercel A, Streinu-Cercel A, Oțelea D, Chifiriuc MC. Multidrug Resistant *Klebsiella pneumoniae* ST101 Clone Survival Chain From Inpatients to Hospital Effluent After Chlorine Treatment. *Front Microbiol*. 2021 Jan 11;11:610296. doi: 10.3389/fmicb.2020.610296. PMID: 33584574; PMCID: PMC7873994. ISSN: 1664-302X. IF (2019): 4.236.
3. Arieti F, Göpel S, Sibani M, Carrara E, Pezzani MD, Murri R, Mutters NT, López-Cerero L, Voss A, Cauda R, Tacconelli E; ARCH working group (Ayola Akim Adegnika, Fabiana Arieti, Nithya Babu Rajendran, Julia Bielicki, Steffen Borrmann, Elena Carrara, Roberto Cauda, Monica Compri, Giulia De Angelis, Raquel Duro, Liliana Galia, Petra Gastmeier, Christian Giske, Siri Göpel, Herman Goossens, Gunnar Kahlmeter, Souha S Kanj, Tomislav Kostyanov, Leonard Leibovici, Jean-Christophe Lucet, Lorena López-Cerero, Rodolphe Mader, Fulvia Mazzaferri, Elena Mazzolini, Marc Mendelson, Rita Murri, Nico T Mutters, Mical Paul, Maria Diletta Pezzani, Elisabeth Presterl, Hanna R Enk, Oana Sandulescu, Le Huu Song, Remco Schrijver, Luigia Scudeller, Mike Sharland, Marcella Sibani, Evelina Tacconelli, Didem Torumkuney, Thirumalaisamy P Velavan, Andreas Voss). White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the outpatient sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother*. 2020 Dec 6;75(Supplement_2):ii42-ii51. doi: 10.1093/jac/dkaa428. ISSN: 0305-7453. eISSN: 1460-2091. Impact factor (2019): 5.439.
4. Sibani M, Mazzaferri F, Carrara E, Pezzani MD, Arieti F, Göpel S, Paul M, Tacconelli E, Mutters NT, Voss A; ARCH working group (Adegnika AA, Gabon L, Arieti F, Rajendran NB, Bielicki J, Borrmann S, Carrara E, Cauda R, Compri M, De Angelis G, Duro R, Frost I, Galia L, Gastmeier P, Giske C, Göpel S, Goossens H, Kahlmeter G, Kanj SS, Kostyanov T, Leibovici L, Lucet JC, López-Cerero L, Mader R, Mazzaferri F, Mazzolini E, Mendelson M, Murri R, Mutters NT, Paul M, Pezzani MD, Presterl E, Renk H, Sandulescu O, Song LH, Sanguinetti M, Schrijver R, Scudeller L, Sharland M, Sibani M, Tacconelli E, Torumkuney D, Velavan TP, Voss A). White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in long-term care facilities-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother*. 2020 Dec 6;75(Supplement_2):ii33-ii41. doi: 10.1093/jac/dkaa427. ISSN: 0305-7453. eISSN: 1460-2091. Impact factor (2019): 5.439.
5. Pezzani MD, Carrara E, Sibani M, Presterl E, Gastmeier P, Renk H, Kanj SS, Velavan TP, Song LH, Leibovici L, Torumkuney D, Kostyanov T, Mendelson M, Tacconelli E; ARCH working group (Adegnika AA, Arieti F, Rajendran NB, Bovo C, Bielicki J, Borrmann S, Carrara C, Cauda R, Compri M, De Angelis G, Duro R, Frost I, Galia L, Gastmeier P, Giske C, Göpel S, Goossens H, Kahlmeter G, Kanj SS, Kostyanov T, Leibovici L, Lucet JC, López-Cerero L, Mader R, Mazzaferri F, Mazzolini E, Mendelson M, Murri R, Mutters NT, Paul M, Pezzani MD, Presterl E, Renk H, Sandulescu O, Song

- LH, Sanguinetti M, Schrijver R, Scudeller L, Sharland M, Sibani M, Tacconelli E, Torumkuney D, Velavan TP, Voss A). White Paper: Bridging the gap between human and animal surveillance data, antibiotic policy and stewardship in the hospital sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother.* 2020 Dec 6;75(Supplement_2):ii20-ii32. doi: 10.1093/jac/dkaa426. ISSN: 0305-7453. eISSN: 1460-2091. Impact factor (2019): 5.439.
6. Keske Ş, Mutters NT, Tsioutis C, Ergönül Ö; EUCIC influenza vaccination survey team (Birgand G, Carrara E, Doting E, Horcajada JP, Mestrovic T, Pshenichnaya N, Sandulescu O). Influenza vaccination among infection control teams: A EUCIC survey prior to COVID-19 pandemic. *Vaccine.* 2020 Dec 14;38(52):8357-8361. doi: 10.1016/j.vaccine.2020.11.003. Epub 2020 Nov 5. PMID: 33183855. ISSN: 0264-410X. Impact factor (2019): 3.143.
 7. Tsioutis C, Birgand G, Bathoorn E, Deptula A, Ten Horn L, Castro-Sánchez E, Săndulescu O, Widmer AF, Tsakris A, Pieve G, Tacconelli E, Mutters NT. Education and training programmes for infection prevention and control professionals: mapping the current opportunities and local needs in European countries. *Antimicrob Resist Infect Control.* 2020 Nov 9;9(1):183. doi: 10.1186/s13756-020-00835-1. ISSN: 2047-2994. eISSN: 2047-2994 Impact factor (2019): 3.594.
 8. Săndulescu O. COVID-19 and cold season preparedness. *Germs.* 2020;10(3):149. doi: 10.18683/germs.2020.1199. ISSN: 2248-2997. Web of Science Core Collection.
 9. Surleac M, Banica L, Casangiu C, Cotic M, Florea D, Sandulescu O, Milu P, Streinu-Cercel A, Vlaicu O, Paraskevis D, Paraschiv S, Otelea D. Molecular Epidemiology Analysis of SARS-CoV-2 Strains Circulating in Romania during the First Months of the Pandemic. *Life (Basel).* 2020 Aug 14;10(8):152. doi: 10.3390/life10080152. eISSN: 2075-1729. Impact factor (2019): 2.991.
 10. Stuurman AL, Bollaerts K, Alexandridou M, Biccler J, Díez Domingo J, Nohynek H, Rizzo C, Turunen T, Riera-Montes M; DRIVE Public Partners (Chironna M, Napoli C, Manini I, Pandolfi E, Icardi G, Panatto D, Mosca S, Lai PL, Orsi A, Mira-Iglesias A, Lópex-Obrador FX, Auvinen R, Skogberg K, Loginov R, Bellino S, Punzo O, Bella A, Redberger-Fritz M, Drăgănescu AC, Săndulescu O, Pițigoi D, Florea D, Vlaicu O, Oțelea D, Bilașco A, Streinu-Cercel A, Luminos MD, Aramă V, Streinu-Cercel A, De Smedt T, De Smedt N, de Lusignan S, Hoang U, Liyanage H, Baum U, Syrjänen RK, Ikonen N, Bonanni P, Ravaldi C, Vannacci A, Bonaiuti R, Levi M, del Amo Morán E, Rodrigo-Pendás JA, Antón A, Andrés C, Uriona-Tuma S. Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19. *Vaccine.* 2020 Sep 22;38(41):6455-6463. doi: 10.1016/j.vaccine.2020.07.063. Epub 2020 Aug 7. ISSN: 0264-410X. eISSN: 1873-2518. Impact factor (2019): 3.143.
 11. Bruno Lina, Alexandre Georges, Elena Burtseva, Marta C Nunes, Melissa K Andrew, Shelly A McNeil, Guillermo M Ruiz-Palacios, Luzhao Feng, Jan Kyncl, Philippe Vanhems, Justin R Ortiz, John Paget, Robert C Reiner, GIHSN 2017–2018 study collaborators (Sélilah Amour, Coulibaly Anderson N'Gattia, Victor Baselga Moreno, Elsa Baumeister, Jalila Ben Khelil, Daria Danilenko, Javier Diez-Domingo, Anca Cristina Drăgănescu, Gideon O Emukule, Zhetpisbayeva Gauhar, M Lourdes Guerrero, Ainara Mira-Iglesias, Lidija Kisteneva, Parvaiz A Koul, Ainagul Kuvatbaeva, Victor Alberto Laguna Torres, Odile Launay, Nezha Lenzi, Shabir Madhi, Zdenka Mandakova, Snežana Medić, Miodjub Ristić, Hyder Mir, Aneta Nitsch-Osuch, Nancy Otieno, Daniela Pițigoi, Andrea Pontoriero, Estela Ramirez, Ben Salah, Oana Sandulescu, Natali Serafin, Wei Shan, Anna Sominina, Svetlana Trushakova, Andrzej Zalewski, Tao Zhang). Complicated hospitalization due to influenza: results from the Global Hospital Influenza Network for the

2017-2018 season. *BMC Infect Dis.* 2020 Jul 2;20(1):465. doi: 10.1186/s12879-020-05167-4. ISSN: 1471-2334. Impact factor (2019): 2.688.

12. Streinu-Cercel A, Apostolescu C, Săndulescu O, Oțelea D, Streinu-Cercel A, Vlaicu O, Paraschiv S, Benea OE, Bacruban R, Nițescu M, Rafila A, Șerban A, Pistol A, Pițigoi D. SARS-CoV-2 in Romania - analysis of the first confirmed case and evolution of the pandemic in Romania in the first three months. *Germs.* 2020 Jun 2;10(2):132-134. doi: 10.18683/germs.2020.1198. ISSN: 2248-2997. Web of Science Core Collection.

13. Pițigoi D, Săndulescu O, Crăciun MD, Drăgănescu A, Jugulete G, Streinu-Cercel A, Vișan A, Rîciu C, Rafila A, Aramă V, Luminos M, Streinu-Cercel A. Measles in Romania - clinical and epidemiological characteristics of hospitalized measles cases during the first three years of the 2016-ongoing epidemic. *Virulence.* 2020;11(1):686-694. doi: 10.1080/21505594.2020.1771948. ISSN: 2150-5594. eISSN: 2150-5608. Impact factor (2018): 4.775.

14. Pițigoi D, Streinu-Cercel A, Ivanciuc AE, Lazăr M, Cherciu CM, Mihai ME, Nițescu M, Aramă V, Crăciun MD, Streinu-Cercel A, Săndulescu O. Surveillance of medically-attended influenza in elderly patients from Romania-data from three consecutive influenza seasons (2015/16, 2016/17, and 2017/18). *Influenza Other Respir Viruses.* 2020 Sep;14(5):530-540. doi: 10.1111/irv.12752. Epub 2020 May 15. doi: 10.1111/irv.12752. ISSN: 1750-2640. eISSN: 1750-2659. Impact factor (2019): 3.288.

15. Surleac M, Czobor Barbu I, Paraschiv S, Popa LI, Gheorghe I, Marutescu L, Popa M, Sarbu I, Talapan D, Nita M, Iancu AV, Arbune M, Manole A, Nicolescu S, Sandulescu O, Streinu-Cercel A, Otelea D, Chifiriuc MC. Whole genome sequencing snapshot of multi-drug resistant *Klebsiella pneumoniae* strains from hospitals and receiving wastewater treatment plants in Southern Romania. *PLoS One.* 2020;15(1):e0228079. doi: 10.1371/journal.pone.0228079. eISSN: 1932-6203. Impact factor (2019): 2.740.

16. Gurzu S, Satala CB, Melit LE, Streinu-Cercel A, Otelea D, Capalna B, Puiac CI, Szederjesi J, Jung I. COVID-19 Like Findings in a Fatal Case of Idiopathic Desquamative Interstitial Pneumonia Associated With IgA Glomerulonephritis in a 13-Month-Old Child. *Front Pediatr.* 2020 Nov 11;8:586666. doi: 10.3389/fped.2020.586666. PMID: 33262964; PMCID: PMC7686237. ISSN: 2296-2360. IF (2019): 2.634

17. Pană A, Pistol A, Streinu-Cercel A, Ileanu BV. Burden of influenza in Romania. A retrospective analysis of 2014/15 - 2018/19 seasons in Romania. *Germs.* 2020;10(4):201-209. doi: 10.18683/germs.2020.1206. PMID: 33134198; PMCID: PMC7572209. eISSN: 2248-2997.

18. Orfanu A, Popescu C, Tiliscan C, Streinu-Cercel A, Arama V, Arama SS. The usefulness of neutrophil/lymphocyte count ratio in the diagnosis and prognosis of bacterial sepsis - An old parameter with new implications. *Revista Romana de Medicina de Laborator.* 2020;28(1):39-48. ISSN: 1841-6624, eISSN: 2284-5623. IF (2019): 0.945

19. Raben D, Hoekstra M, Combs L, Sullivan AK, Lazarus JV, Lambert J, Simoes D, Streinu-Cercel A, Rockstroh JK, HepHIV Conf Organizing Comm ; EuroTEST Steering Comm ; INTEGRATE Steering Comm. A call to action toward integrated testing and earlier care for viral hepatitis, HIV, STIs and TB. *HIV Medicine.* 2020;21(6):403-408. DOI: 10.1111/hiv.12844. ISSN: 1464-2662. eISSN: 1468-1293. IF (2019): 3.556.

20. Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, Streinu-Cercel A, Bourgeois S, Buti M, Crespo J, Pascasio JM, Sarrazin C, Vanwolleghem T, Shukla U, Fry J, Yogarathnam JZ. JNJ-56136379, an HBV Capsid Assembly Modulator, is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection. *Gastroenterology.* 2020 Apr 25:S0016-5085(20)30519-9. doi:

10.1053/j.gastro.2020.04.036. ISSN / eISSN: 0016-5085 / 1528-0012. Impact factor 19.809.

21. Streinu-Cercel A. SARS-CoV-2 in Romania - situation update and containment strategies. *Germs*. 2020 Mar 2;10(1):8. ISSN: 2248-2997. doi: 10.18683/germs.2020.1179.

22. Hayes R, Schmidt AJ, Pharris A, Azad Y, Brown AE, Weatherburn P, Hickson F, Delpach V, Noori T; The ECDC Dublin Declaration Monitoring Network (...Mardarescu M, Streinu-Cercel A, Simic D...). Estimating the 'PrEP Gap': how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. *Euro Surveill*. 2019 Oct;24(41). doi: 10.2807/1560-7917.ES.2019.24.41.1900598. Erratum in: *Euro Surveill*. 2019 Nov;24(46).IF 2018:7.4

23. Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, Morozov V, Klinker H, Sollano JD, Streinu-Cercel A, Cheinquer H, Xie Q, Wang YM, Wei L, Jia JD, Gong G, Han KH, Cao W, Cheng M, Tang X, Tan D, Ren H, Duan Z, Tang H, Gao Z, Chen S, Lin S, Sheng J, Chen C, Shang J, Han T, Ji Y, Niu J, Sun J, Chen Y, Cooney EL, Lim SG. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. *Clin Gastroenterol Hepatol*. 2020 Feb;18(2):457-467.e21. doi: 10.1016/j.cgh.2019.07.010. IF (2019): 8.549. ISSN: 1542-3565. eISSN: 1542-7714.

• **Scientific works of interest presented at national and international congresses during 2020**

1. Streinu-Cercel A, Bazinet M, Elsner C, Dittmer U, Vaillant A. Interferon free clearance of HDV RNA and HBsAg seroconversion in a cirrhotic subject with chronic HBV / HDV co-infection with TDF and REP 2165-mg. Meeting Abstract: 827. Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). Online. Nov 13-16, 2020. Abstract published in: *Hepatology*. 2020;72(S1):505A-506A. ISSN: 0270-9139. eISSN: 1527-3350. IF (2019): 14.679.

2. Lim YS, Choi J, Choi WM, Brunetto MR, Hou JL, Agarwal K, Chang TT, Ning Q, Lim SG, Streinu-Cercel A, Flaherty JF, Wang HY, Gao B, Gaggar A, Suri V, Coffin CS, Ferrey MAB, Chan, HLY. Impact of pre-treatment plasma HBV DNA levels on the rate of ALT normalization during antiviral therapy with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB). Meeting Abstract: 796. Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). Online. Nov 13-16, 2020. Abstract published in: *Hepatology*. 2020;72(S1):485A-485A. ISSN: 0270-9139. eISSN: 1527-3350. IF (2019): 14.679.

3. Streinu-Cercel A, Săndulescu O, Oană AA*, Manolache D, ISARIC author group, Streinu-Cercel A. Dynamic trends of the clinical profiles of patients hospitalized for COVID-19. (equal contributions). Oral presentation. 16th Edition of the Scientific Days of the National Institute for Infectious Diseases "Prof. Dr. Matei Balș". Online meeting. 26-30 October 2020. Abstract volume ISSN 2457-8525, pag 3-4.

4. Streinu-Cercel A, Săndulescu O, Gorgan C, Streinu-Cercel A. Treatment with favipiravir in patients hospitalized for COVID-19. (equal contributions). Oral presentation. 16th Edition of the Scientific Days of the National Institute for Infectious Diseases "Prof. Dr. Matei Balș". Online meeting. 26-30 October 2020. Abstract volume ISSN 2457-8525, pag 13.

5. Draganescu AC, Sandulescu O, Florea D, Vlaicu O, Streinu-Cercel A, Bilasco A, Miron VD, Otelea D, Arama V, Luminos ML, Streinu-Cercel A. Surveillance of the

circulation of influenza viruses in the 2019/20 season in National Institute of Infectious Diseases “Prof. Dr. Matei Balș”. (equal contributions). Oral presentation. 16th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof. Dr. Matei Balș”. Online meeting. 26-30 October 2020. Abstract volume ISSN 2457-8525, pag 17-18.

6. Georgescu I, Streinu-Cercel A, Bradu LM, Sandulescu O, Motoi MM, Apostolescu C, Manu B, Camburu C, Streinu-Cercel. Covid-19, severe and prolonged form of disease – case report. Oral presentation. 16th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof. Dr. Matei Balș”. Online meeting. 26-30 October 2020. Abstract volume ISSN 2457-8525, pag 27-28.

• **Research projects performed in INBI MB during 2020 with topics related to the BWTC**

1. 2020-2021. University Medical Center Utrecht. Multi-centre European study of MAJOR Infectious Disease Syndromes (MERMAIDS) – Acute Respiratory Infections (MERMAIDS ARI) 2.0. Funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003589.

2. 2018-2020. “Development of Robust and Innovative Vaccine Effectiveness (DRIVE)”, financed through Innovative Medicines Initiative (IMI) 2 Grant Agreement No. 777363. (INBI MB was partner, project coordinator was Fundación Para el Fomento de Investigación Sanitaria y Biomédica de la Comunitat Valenciana - FISABIO, Valencia, Spain).

3. 2016-2020. “GIHSN prospective epidemiological active surveillance study in Romania”. Global Influenza Hospital Surveillance Network (GIHSN) 2018-2019. Financed through Foundation for influenza epidemiology, Fondation de France, Sanofi Pasteur.

4. 2018-2021 “Selecția și diseminarea genelor de rezistență la antibiotice de la nivelul stațiilor de epurare a apelor uzate în mediul acvatic și sectorul clinic”. (Selection and dissemination of antibiotic resistance genes from waste water facilities to aquatic medium and clinical sector) PN-III-P4-ID-PCCF-2016-0114. Financed through national budget PNCDI III, Programme 4 “Cercetare fundamentală și de frontieră”, Proiecte complexe de cercetare de frontieră. (INBI MB is partner, project coordinator is University of Bucharest).

5. april 2018 –present. “Surveillance of Hepatitis C Antiviral Resistance, Epidemiology and Methodologies” (SHARED), part of the international research grant “Development, Validation and Worldwide Dissemination of a Standard and Next Generation Deep Sequence Assay of HCV, and Application to a Longitudinal Analysis in a Very Well Characterized PWID Cohort” financed by Genome BC. (coordinated by Dr. Anita Howe, British Columbia Center for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada).

6. 2018-2021 Project POCU/91/4/8/108129: “Competență și calitate în serviciile medicale prioritare prin formarea specifică a personalului medical în domeniul bolilor infecțioase”. (Competence and quality in priority medical services through targeted training of medical staff in infectious diseases) Cod SMIS 2014+: 108129. Financed through the Social European Fund, Human Capital Operational Programme (POCU) 2014-2020.

Confidence-Building Measure "D"

(Deleted)

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

(a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;

(b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures ³⁰	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	Yes	Yes	Yes	No
(b) Exports of micro-organisms ³¹ and toxins	Yes	Yes	No	Yes

³⁰ Including guidelines.

(c) Imports of micro-organisms ¹¹ and toxins	Yes	Yes	No	Yes
(d) Biosafety ³² and biosecurity ³³	Yes	Yes	Yes	No

Name of legislation, regulations and other measures

No	Specification	No	Year	Topic
1	Council Regulation (EC)	428	2009	Setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items
2	Commission Delegated Regulation (EU) 2019/2199	1749	2020	Amending Council Regulation (EC) No 428/2009 setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items
3	Council Regulation (EU) 2015/1861	1861	2015	Modifying Council Regulation (EU) 267/2012 regarding restrictive measures against Iran
4	Government Ordinance	119	2010	Regarding the control regime of dual use operations
5	Law	197	2011	Approving Government Ordinance No 119/2010
6	Government Ordinance	12	2012	Modifying Government Ordinance No 119/2010
7	Law	35	2013	Approving Government Ordinance No 12/2012
8	Order of the Minister of Foreign Affairs	914	2012	Approving the regulation for implementing the provisions of Government Ordinance No 119/2010 regarding the control regime of dual-use operations
9	Order of the Minister of Foreign Affairs	358	2016	Approving the methodological norms for applying the provisions of Council Regulation (EU) 2015/1861 modifying Reg. (EU) 267/2012 regarding restrictive measures against Iran

³¹ Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

³² In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

³³ In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

Confidence-Building Measure "F"

Declaration of past activities in offensive and/or defensive biological research and development programmes

In the interest of increasing transparency and openness, States parties shall declare whether or not they conducted any offensive and/or defensive biological research and development programmes since 1 January 1946.

If so, States parties shall provide information on such programmes, in accordance with Form F.

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State Party.

2. Past offensive biological research and development programmes:
 - Yes/No

 - Period(s) of activities

 - Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

3. Past defensive biological research and development programmes:
 - Yes/No

 - Period(s) of activities

 - Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Confidence-Building Measure "G"

Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

Form G

Declaration of vaccine production facilities

1. Name of facility: [The "Cantacuzino" National Medico-Military Institute for Research and Development, Bucharest](#)

2. Location (mailing address): [Splaiul Independentei 103 – 105, 050096, Sector 5, Bucharest, Romania](#)

3. General description of the types of diseases covered:

While the “Cantacuzino” NMMIRD has a production facility and has, in the past, produced several vaccines, the facility is not currently operational. A Trivalent Northern Hemisphere Influenza Vaccine (egg-adapted influenza virus) was manufactured at this facility, as was a monovalent vaccine for the pandemic A/H1N1v strain. A BCG vaccine was also manufactured at the facility.

Form G

Declaration of vaccine production facilities

1. Name of facility: [SC Pasteur – Filiala Filipesti Srl, working point Bucharest](#)

2. Location (mailing address): [333 Giulesti Str., 060269 Bucharest, sector 6, Romania;](#)
[Phone: +40212209909; fax: +40212206915; email: office@pasteur.ro](#)

3. General description of the types of diseases covered: [animal diseases \(viral, bacterial diseases\)](#).
-

Form G

Declaration of vaccine production facilities

1. Name of facility: [ROMVAC COMPANY S.A.](#)
 2. Location (mailing address): [Soseaua Centurii \(Centurii Drive\) No. 7, Voluntari, IF-077109, Romania; email: \[romvac@romvac.ro\]\(mailto:romvac@romvac.ro\)](#);
 3. General description of the types of diseases covered: [Carboromvac – live antrax vaccine for animals: cattle, sheep, goats, horses and swine.](#)
-